Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Angelini Pharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Angelini Pharma
Italy Flag
Country
Country
Italy
Address
Address
Via Guardapasso, 1 - 04011 Aprilia (LT) Italy
Telephone
Telephone
+39 0692040401
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The collaboration combines Angelini Pharma’s expertise in neurological diseases with JCR Pharmaceuticals’ J-Brain Cargo®, blood-brain barrier penetrating technology to develop highly innovative brain-penetrant biologic therapeutics in epilepsy.


Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Recipient: JCR Pharmaceuticals

Deal Size: $505.5 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cenobamate – under the brand name ONTOZRY® – has been commercialized in five major European countries such as Germany, the UK, Italy, Spain, and France, accounting for about 73 percent of the total value of the continent’s epilepsy market.


Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Ontozry

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: SK Biopharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 09, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Ontozry (cenobamate) is a novel small molecule that provides a dual, complementary mechanism of action aimed at treatment of seizures also known as focal-onset seizures.


Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Ontozry

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Pivotal trial has demonstrated that Ontozry (cenobamate) at doses of 100 mg, 200 mg, and 400 mg/day significantly improved seizure control versus placebo for adult patients with focal-onset seizures taking 1-3 ASMs.


Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Ontozry

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Following Angelini Pharma’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).


Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Xcopri

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Arvelle Therapeutics

Deal Size: $960.0 million Upfront Cash: $960.0 million

Deal Type: Acquisition January 04, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age. In addition to the new indication, Latuda was also granted an additional year of marketing protection.


Lead Product(s): Lurasidone Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: Latuda

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Sunovion Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 12, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 for the treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdom and Russia.


Lead Product(s): Gaboxadol

Therapeutic Area: Genetic Disease Product Name: OV101

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Ovid Therapeutics

Deal Size: $232.0 million Upfront Cash: $20.0 million

Deal Type: Licensing Agreement July 13, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence.


Lead Product(s): Camphor,Capsicum oleoresin,Menthol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: GSK

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 10, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY